One of the most ubiquitous kids’ magazines from my childhood was “Highlights for Children.” These magazines were a mainstay in the offices of doctors and dentists everywhere. Upon entering any ...

With several disease-modifying therapies available for transthyretin amyloid cardiomyopathy (ATTR-CM) -- and more waiting in the wings -- choosing one has become a new challenge, with softer endpoints ...

Narrow-moat Alnylam reported solid first-quarter results with net product revenue growing 28% year over year to $469 million, thanks to robust demand for its ATTR amyloidosis franchise, which grew 45% ...

The US Food and Drug Administration (FDA) has approved a supplemental new drug application for vutrisiran for the treatment of wild-type or hereditary transthyretin-mediated amyloid cardiomyopathy ...

There was no significant difference in overall survival following the transplant in patients with cardiac amyloidosis and those without cardiac amyloidosis. Survival following a heart transplant in ...

Checking the value of your U.S. savings bonds is straightforward and can be done online through the TreasuryDirect website. Once logged into the portal, you’ll either automatically see the value of ...

This rare condition can’t be cured, but its symptoms can be treated. Take this assessment to learn what more you can do to manage the condition. Before you were diagnosed with transthyretin ...

The US Food and Drug Administration (FDA) has declined to approve the RNA interference (RNAi) therapeutic agent patisiran (Onpattro, Alnylam Pharmaceuticals) for treatment of transthyretin-mediated ...

Part of Billionaire's Row and Central Park. Image © Itrytohelp32 via WIkipedia under license CC BY-SA 4.0 What we build can be metaphoric—often intentionally ...